Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Sosman JA, et al. Among authors: chmielowski b. N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302. N Engl J Med. 2012. PMID: 22356324 Free PMC article. Clinical Trial.
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma.
Eckardt MA, Graham DS, Klingbeil KD, Lofftus SY, McCaw TR, Bailey MJ, Goldring CJ, Kendal JK, Kadera BE, Nelson SD, Dry SM, Kalbasi AK, Singh AS, Chmielowski B, Eilber FR, Eilber FC, Crompton JG. Eckardt MA, et al. Among authors: chmielowski b. Ann Surg Oncol. 2023 May;30(5):3097-3103. doi: 10.1245/s10434-022-12977-0. Epub 2022 Dec 29. Ann Surg Oncol. 2023. PMID: 36581724
[No title available]
[No authors listed] [No authors listed] PMID: 36690841
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Hong DS, et al. Among authors: chmielowski b. Clin Cancer Res. 2023 Jun 13;29(12):2210-2219. doi: 10.1158/1078-0432.CCR-22-3313. Clin Cancer Res. 2023. PMID: 37000164 Free PMC article. Clinical Trial.
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. Søndergaard JN, et al. Among authors: chmielowski b. J Transl Med. 2010 Apr 20;8:39. doi: 10.1186/1479-5876-8-39. J Transl Med. 2010. PMID: 20406486 Free PMC article.
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.
Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Ribas A, et al. Among authors: chmielowski b. J Transl Med. 2010 Sep 27;8:89. doi: 10.1186/1479-5876-8-89. J Transl Med. 2010. PMID: 20875102 Free PMC article. Clinical Trial.
133 results